| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10351517 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(2 years from now) | |
| US8877806 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(2 years from now) | |
| US9604917 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(2 years from now) | |
| US8440715 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2031
(7 years from now) | |
| US10512609 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(13 years from now) | |
| US10195151 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(13 years from now) | |
| US10912754 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(14 years from now) | |
| US10959976 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(14 years from now) | |
| US10940133 | JAZZ | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(16 years from now) | |
Sunosi is owned by Jazz.
Sunosi contains Solriamfetol Hydrochloride.
Sunosi has a total of 9 drug patents out of which 0 drug patents have expired.
Sunosi was authorised for market use on 17 June, 2019.
Sunosi is available in tablet;oral dosage forms.
Sunosi can be used as treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment, to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily, to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa), treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily.
Drug patent challenges can be filed against Sunosi from 2023-06-18.
The generics of Sunosi are possible to be released after 19 March, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstru...
Dosage: TABLET;ORAL
SUNOSI family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(13 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(14 years from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(15 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(16 years from now) | |
Sunosi is owned by Axsome Malta.
Sunosi contains Solriamfetol Hydrochloride.
Sunosi has a total of 4 drug patents out of which 0 drug patents have expired.
Sunosi was authorised for market use on 17 June, 2019.
Sunosi is available in tablet;oral dosage forms.
Sunosi can be used as treatment of excessive daytime sleepiness with a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily, treatment of excessive daytime sleepiness by administering solriamfetol to a subject having mild, moderate, or severe renal impairment, treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropane.
Drug patent challenges can be filed against Sunosi from 2023-06-18.
The generics of Sunosi are possible to be released after 19 March, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness with a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime ...
Dosage: TABLET;ORAL
SUNOSI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic